Abatacept
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Abatacept: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Abatacept is a selective T-cell costimulation modulator (CTLA4-Ig fusion protein), clinically established for the treatment of rheumatoid arthritis in major global markets. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, with 1 clinical trial and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid Arthritis (established clinical use; formal indication data not available in this dataset) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this dataset. Based on published literature included in this evidence pack, Abatacept is a CTLA4-Ig fusion protein that selectively inhibits T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby blocking the CD28 co-stimulatory signal required for full T-cell activation. It is well established for the treatment of rheumatoid arthritis (RA) and related autoimmune inflammatory conditions globally.
Rheumatoid vasculitis (RV) is a severe extra-articular manifestation of long-standing, seropositive RA, driven by immune complex deposition and T-cell–mediated vascular inflammation. Because abatacept targets the same CD4+ T-cell activation pathways that underlie RA joint inflammation, there is a plausible mechanistic basis for potential benefit in RV. The shared autoimmune T-cell–driven pathology makes this a biologically rational repurposing hypothesis.
Multiple published case reports document abatacept use in confirmed RV, including at least two cases of rapid clinical improvement (PMID 22124545, PMID 29930884). However, one case report also documents new-onset vasculitis arising during abatacept therapy (PMID 27052429), introducing an important paradoxical reaction concern that requires careful clinical interpretation before broader use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not Yet Recruiting | 80 | Immunosuppressant management (including abatacept) in rheumatology patients undergoing elective shoulder arthroplasty; assesses rheumatologic flares, pain scores (VAS), functional outcomes (PROMIS), wound complications, and surgical site infections |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29930884 | 2018 | Case Report | Cureus | Abatacept used as therapeutic option for biopsy-confirmed cutaneous RV in RA patient with common variable immunodeficiency; ritual was contraindicated due to immunodeficiency, and abatacept provided benefit |
| 22124545 | 2012 | Case Report | Modern Rheumatology | Rapid clinical improvement of RV on abatacept in a woman refractory to MTX, TNF inhibitors, steroids, plasmapheresis, and IL-6 inhibitor; near normalization of inflammatory markers achieved |
| 27052429 | 2016 | Case Report | Joint Bone Spine | New-onset RV during abatacept therapy, with subsequent improvement after switch to rituximab; highlights potential paradoxical effect |
| 30119075 | 2018 | Case Report | Ophthalmic Plastic and Reconstructive Surgery | RA patient on abatacept developed bilateral orbital lesions; biopsy showed vasculitis with mixed inflammatory infiltrate and eosinophilia; initial response to cyclophosphamide followed by progression |
| 36418100 | 2023 | Case Report | Internal Medicine (Tokyo) | MPO-ANCA-associated nephritis occurring during concurrent abatacept and adalimumab therapy for RA; tocilizumab attenuated the nephritis |
| 34068884 | 2021 | Review | Journal of Clinical Medicine | Review of episcleritis and scleritis as ocular manifestations of RA; discusses biologics including abatacept in managing inflammatory ocular disease with vasculitic features |
| 31174819 | 2018 | Review | Best Practice & Research Clinical Rheumatology | CNS involvement in RA including cerebral vasculitis; discusses biological agents and CNS complication risks, including abatacept |
| 24854356 | 2014 | Cohort Study | Annals of the Rheumatic Diseases | ANA testing predicts bDMARD-associated lupus and vasculitis in RA patients; abatacept included in the biologic cohort evaluation |
| 24493331 | 2015 | Case-based Review | Clinical Rheumatology | Abatacept as successful therapy for myositis; discusses mechanistic rationale and off-label use in autoimmune conditions overlapping with RA |
| 41782910 | 2026 | Review (Delphi Consensus) | Therapeutic Advances in Musculoskeletal Disease | Stratified expert recommendations for post-TNFi treatment in RA; abatacept identified as a key alternative option |
Taiwan Market Information
Abatacept is not currently marketed in Taiwan (0 approved licenses in the TFDA database as of the data cutoff date).
Abatacept (Orencia®) holds regulatory approval in the United States (FDA) and European Union (EMA) for rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Taiwan market entry would require a formal TFDA regulatory submission.
Safety Considerations
Please refer to the SmPC for safety information.
Important Note: TFDA-specific prescribing information (warnings and contraindications) was not available at the time of this report (Data Gap DG001). Based on published literature, a clinically meaningful safety signal exists: at least one case report documents new-onset rheumatoid vasculitis occurring paradoxically during abatacept therapy (PMID 27052429), and another documents MPO-ANCA nephritis arising during abatacept use (PMID 36418100). Careful patient selection, baseline autoantibody profiling, and close monitoring for paradoxical inflammatory events are warranted before any clinical use in RV.
Conclusion and Next Steps
Decision: Hold
Rationale: Direct evidence for abatacept in rheumatoid vasculitis is currently limited to a small number of case reports (Evidence Level L4), with no controlled clinical trials specifically addressing this indication. The presence of paradoxical RV onset during abatacept therapy further complicates the risk-benefit assessment at this stage.
To proceed, the following is needed:
- Prospective case series or registry study in biopsy-confirmed rheumatoid vasculitis patients treated with abatacept
- TFDA prescribing information (warnings and contraindications) to complete the safety profile for Taiwan-specific regulatory assessment
- Mechanistic clarification of abatacept’s effect on immune complex deposition and vessel wall inflammation, the core pathology of RV
- Resolution of the paradoxical vasculitis signal: characterization of patients at risk for RV onset or exacerbation on abatacept
- If evidence accumulates, regulatory consultation with TFDA for an orphan or compassionate-use pathway, given the severity and rarity of RV
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.